Eloxx Pharmaceuticals Inc (ELOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2013 | 06-2013 | 12-2012 | 06-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | N/A | -6,123 | -3,350 | N/A | -2,560 |
| Depreciation Amortization | 150 | 294 | 130 | N/A | 110 |
| Accounts payable and accrued liabilities | N/A | 43 | N/A | N/A | N/A |
| Other Working Capital | 500 | -216 | 1,710 | N/A | -20 |
| Other Operating Activity | 650 | 2,099 | 310 | 0 | 180 |
| Operating Cash Flow | $1,300 | $-3,903 | $-1,200 | $N/A | $-2,290 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | -1 | -1 | N/A | -4 |
| Purchase Sale Intangibles | N/A | -528 | N/A | N/A | N/A |
| Other Investing Activity | -250 | -528 | -249 | 0 | -226 |
| Investing Cash Flow | $-250 | $-529 | $-250 | $N/A | $-230 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 4,045 | N/A | N/A | N/A |
| Other Financing Activity | 6,860 | -12 | 90 | 0 | 470 |
| Financing Cash Flow | $6,860 | $4,033 | $90 | $N/A | $470 |
| Beginning Cash Position | N/A | 2,001 | 2,000 | N/A | 3,610 |
| End Cash Position | N/A | 1,602 | 640 | N/A | 1,550 |
| Net Cash Flow | $7,910 | $-399 | $-1,360 | $N/A | $-2,050 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,300 | -3,903 | -1,200 | N/A | -2,290 |
| Capital Expenditure | N/A | -1 | N/A | N/A | N/A |
| Free Cash Flow | 1,300 | -3,904 | -1,200 | 0 | -2,290 |